Immunome Inc. (IMNM): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMNM Stock Price Chart Interactive Chart >
IMNM Price/Volume Stats
|Current price||$3.42||52-week high||$27.80|
|Prev. close||$3.25||52-week low||$2.09|
|Day high||$3.49||Avg. volume||72,836|
|50-day MA||$4.14||Dividend yield||N/A|
|200-day MA||$11.96||Market Cap||41.47M|
Immunome Inc. (IMNM) Company Bio
Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.
Most Popular Stories View All
IMNM Latest News Stream
|Loading, please wait...|
IMNM Latest Social Stream
View Full IMNM Social Stream
Latest IMNM News From Around the Web
Below are the latest news stories about Immunome Inc that investors may wish to consider to help them evaluate IMNM as an investment opportunity.
Immunome Inc (NASDAQ: IMNM ) shares rose before falling after reporting results from testing its experimental three-antibody cocktail against live versions of the COVID-19 omicron variant . CEO Purnanand Sarma said that there had been a significant reduction in the number of antibody therapeutics under emergency use authorization that are active against omicron in recent weeks. That trend, he said, demonstrates … Full story available on Benzinga.com
Immunome (IMNM) said in vitro data showed effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two
During the past two years, Immunonome has received more than $17.5 million from the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to support the company's development of the new drug candidate.
Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing
EXTON, Pa., February 08, 2022--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced in vitro data demonstrating effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two external laboratories (Boston University’s National Emerging Infectious Diseases Laboratories and Washington University1).
The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid…
IMNM Price Returns